Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
| Autor: | Ayse Karatas, Yahya Buyukasik, Umit Yavuz Malkan, Elifcan Aladag, Hakan Goker, Haluk Demiroglu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Urology Second transplant 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation second autologous stem cell transplantation medicine Overall survival Immunology and Allergy Multiple myeloma business.industry lcsh:RC633-647.5 Complete remission Treatment options Hematology General Medicine lcsh:Diseases of the blood and blood-forming organs medicine.disease multiple myeloma 030220 oncology & carcinogenesis Medicine Disease assessment business Progressive disease 030215 immunology Research Article |
| Zdroj: | Open Medicine Hematology, Transfusion and Cell Therapy, Vol 42, Iss, Pp 64-(2020) Open Medicine, Vol 16, Iss 1, Pp 192-197 (2021) |
| ISSN: | 2391-5463 |
| Popis: | Background Autologous stem cell transplantation (ASCT) is one of the standard treatments of choice for eligible multiple myeloma (MM) patients. Herein, we aimed to analyze MM patients at our center and compare the clinical outcomes of single and double ASCT patients. Materials and methods Patients who were diagnosed as having MM and had undergone single or double ASCT in our clinic between the years 2003 and 2020 were retrospectively examined. Results In this study, the median time of second ASCT is approximately 3.6 years from the first ASCT. Overall survival (OS) duration of the single and double transplanted groups was 4,011 ± 266 vs 3,526 ± 326 days, respectively (p: 0.33). Progression-free survival (PFS) duration of the single and double transplanted groups was 2,344 ± 228 vs 685 ± 120 days, respectively (p: 0.22). Disease assessment after ASCT stable or progressive disease, partial remission, and very good partial or complete remission (CR) in single and double ASCT groups was 62/44/105 and 8/4/5, respectively (p: 0.22). Conclusion The present study points out that the second ASCT treatment option for MM patients may not be effective as suggested, especially in the era of novel MM drugs, since our results come from the past data that novel drugs were not exist. In conclusion, we found no benefit with second ASCT in MM patients in terms of PFS and OS or CR rates, and the novel anti-myeloma drugs might decrease the need for a second transplant. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|